Purchase this article with an account.
S. Yamamoto, M. Kubota, K. Okada, T. Baba, Y. Mitamura; Efficacy of Subtenon Infusion of Triamcinolone Acetonide Prior to Repeat Photodynamic Therapy for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1818.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine the efficacy of subtenon infusion of triamcinolone acetonide (TA) prior to a repeat photodynamic therapy (PDT) as a treatment for age-related macular degeneration (AMD).
Fifty-nine eyes of 59 patients with AMD with prior unsuccessful PDT were treated with PDT again. Twenty-one eyes were treated with PDT and a subtenon infusion of 12mg of TA, and 38 eyes were treated with PDT alone. The best-corrected visual acuity (BCVA) in logMAR units and foveal thickness (FT) determined by optical coherence tomography were examined before, and at 1 and 3 months after treatment.
In the TA-infused group, the mean BCVA was 1.02 before treatment, and 1.10 at 1 month, and 1.11 at 3 months after treatment. In the PDT-alone group, the mean VA was 0.99, 0.95, and 0.98 at the same times. There was no significant improvement of VA in both groups. In the TA-infused group, the mean FT was reduced to 84.8% of the pre-treatment value at 1 month, and 77.7% at 3 months after treatment. In the PDT-alone group, the mean FT was reduced to 85.0% at 1 month and 79.7% at 3 months after treatment. There was no significant difference in the reduction of FT between two groups. Two patients in the TA-infused group developed an intraocular pressure of >24 mmHg, which was treated with topical anti-glaucoma therapy.
These findings indicate that there may be no benefit in the simultaneous subtenon infusion of TA with a repeat PDT for AMD.
This PDF is available to Subscribers Only